Shanghai RAAS reported H1 2024 revenue of ¥4.25 billion (+9.02% YoY) and net profit of ¥1.24 billion (+0.15% YoY), with Haier Group becoming the new controlling shareholder and continued strong growth in blood products and R&D investment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.